SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 127.93 |
| Enterprise Value ($M) | 71.06 |
| Book Value ($M) | 224.01 |
| Book Value / Share | 5.18 |
| Price / Book | 0.57 |
| NCAV ($M) | 211.01 |
| NCAV / Share | 4.88 |
| Price / NCAV | 0.61 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.63 |
| Return on Assets (ROA) | -0.37 |
| Return on Equity (ROE) | -0.40 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.44 |
| Current Ratio | 7.44 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 247.65 |
| Assets | 260.65 |
| Liabilities | 36.65 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -142.60 |
| Net Income | -127.48 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -114.25 |
| Cash from Investing | -160.90 |
| Cash from Financing | 337.11 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Westlake BioPartners Fund I, L.P. | 10.50 | ||
| 13G | Jpmorgan Chase & Co | 5.50 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 167,458 | 640,307 | 26.15 | |
| 43,182 | 195,566 | 22.08 | |
| 44,229 | 323,800 | 13.66 | |
| 51,599 | 235,526 | 21.91 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KPTI – Karyopharm Therapeutics Inc. | KRYS – Krystal Biotech, Inc. |
| KURA – Kura Oncology, Inc. | LVTX – LAVA Therapeutics N.V. |
| LXRX – Lexicon Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io